Page 38 - Diffuse Largeb Cell Lymphoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IMV Inc Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

IMV Inc Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomAndrew hallDelphine davanMatthew matasarRwjbarnabas healthWall streetNova scotiaDiffuse largeb cell lymphomaNew york cityBlood disordersRutgers cancer instituteNew jerseyObjective response rateComplete response

Form 6-K Cellectis S A For: Dec 13

Form 6-K Cellectis S A For: Dec 13
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalCroix jarryMeeting of the american society hematologySecurities exchange commissionSecurities exchangeAmsterdam university medical center vumcCommission file numberForeign private issuerSecurities exchange actFile numberExact nameAnnounces positive preliminary clinical dataAnnual meetingAmerican societyNatural killer

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split

IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Toronto stock exchangeNova scotiaNasdaq capital marketDiffuse largeb cell lymphoma

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll.

United statesMohamed zakiGenmab duobodyData from the observational national lymphocare studyAmerican society of hematologyLymphoma research foundationMacrophage propertiesj immunolNational institutes of healthDrug administrationBlood cancer press kitExchange commissionLeukaemia foundationDevelopment of novel antiEuropean medicines agencyAmerican societySubcutaneous epcoritamab

Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in

COPENHAGEN, Denmark (BUSINESS WIRE) Epcoritamab featured in multiple data disclosures, including four oral presentationsResults presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell.

United statesNew orleansNew jerseyDavid freundelJudith klimovskyExposition of the american society hematologyProduct communicationsMacrophage propertiesj immunolData from the observational national lymphocare studyNational institutes of healthDrug administrationExchange commissionLeukaemia foundationDevelopment of novel antiEuropean medicines agencyLymphoma research foundation